CD19 and B-cell acute lymphoblastic leukemia: The most compelling success of CAR-T cells therapy has been achieved in CD19-specific CAR-T cells for R/R B-cell acute lymphoblastic leukemia (B-ALL) with a complete remission (CR) rates of 70 ~ 94% [2,3].